BioScrip, Inc. (BIOS) Scheduled to Post Earnings on Monday
BioScrip, Inc. (NASDAQ:BIOS) is set to release its earnings data before the market opens on Monday, November 6th. Analysts expect BioScrip to post earnings of ($0.10) per share for the quarter.
BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). The firm had revenue of $218.11 million for the quarter, compared to analyst estimates of $220.05 million. The company’s revenue was down 6.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.14) earnings per share. On average, analysts expect BioScrip to post $-0.55 EPS for the current fiscal year and $-0.17 EPS for the next fiscal year.
Shares of BioScrip, Inc. (NASDAQ:BIOS) opened at 2.51 on Monday. BioScrip, Inc. has a 52-week low of $0.98 and a 52-week high of $3.39. The stock’s 50 day moving average is $2.63 and its 200 day moving average is $2.44. The stock’s market capitalization is $319.96 million.
In other news, Director Coliseum Capital Management, L sold 2,846,941 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $2.93, for a total value of $8,341,537.13. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Michael G. Bronfein sold 27,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $2.69, for a total transaction of $72,630.00. Following the completion of the transaction, the director now owns 129,669 shares in the company, valued at $348,809.61. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,760,419 shares of company stock valued at $11,144,519. 0.80% of the stock is owned by company insiders.
A number of equities research analysts recently weighed in on BIOS shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $4.00 price target (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. ValuEngine lowered shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BidaskClub lowered shares of BioScrip from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 1st. Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a report on Wednesday, July 5th. Finally, SunTrust Banks, Inc. raised shares of BioScrip from a “hold” rating to a “buy” rating and raised their price objective for the stock from $3.25 to $3.75 in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $3.75.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.